nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Accurate Determination of Prostate Size Via Digital Rectal Examination and Transrectal Ultrasound
|
Roehrborn, Claus G |
|
1998 |
1-20 |
4S1 |
p. 19-22 4 p. |
artikel |
2 |
African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials
|
Powell, Isaac J |
|
2001 |
1-20 |
4S1 |
p. 178-181 4 p. |
artikel |
3 |
Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
|
Kelloff, Gary J |
|
2001 |
1-20 |
4S1 |
p. 46-51 6 p. |
artikel |
4 |
Analysis and presentation
|
Friberg, Sten |
|
1997 |
1-20 |
4S1 |
p. 54-65 12 p. |
artikel |
5 |
Androgen antagonists: Potential role in prostate cancer prevention
|
Trump, Donald L |
|
2001 |
1-20 |
4S1 |
p. 64-67 4 p. |
artikel |
6 |
Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials
|
Ali, Iqbal Unnisa |
|
2001 |
1-20 |
4S1 |
p. 143-147 5 p. |
artikel |
7 |
Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer
|
Fleshner, Neil Eric |
|
2001 |
1-20 |
4S1 |
p. 90-94 5 p. |
artikel |
8 |
Apoptosis as a biomarker in chemoprevention trials
|
Riss, Terry L |
|
2001 |
1-20 |
4S1 |
p. 141-142 2 p. |
artikel |
9 |
A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment, and design issues
|
Costello, Anthony J |
|
2001 |
1-20 |
4S1 |
p. 182-184 3 p. |
artikel |
10 |
Army and Air Force Leadership in The Prostate Cancer Prevention Trial 1 1 The opinions expressed herein are those of the authors and do not necessarily reflect those of the Departments of the Army or Defense.
|
Allerton, Jeffrey |
|
1998 |
1-20 |
4S1 |
p. 64-66 3 p. |
artikel |
11 |
Assessment of endpoints for clinical trials for localized prostate cancer
|
Schellhammer, Paul |
|
1997 |
1-20 |
4S1 |
p. 27-38 12 p. |
artikel |
12 |
Assessment of hormone refractory prostate cancer
|
Newling, Don |
|
1997 |
1-20 |
4S1 |
p. 46-53 8 p. |
artikel |
13 |
Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer
|
Weiss, Heidi L |
|
2001 |
1-20 |
4S1 |
p. 220-223 4 p. |
artikel |
14 |
Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride 1 1 Financial support for these studies was provided by Merck & Co., Inc., Rahway, New Jersey 2 2 This article was originally published in Urology, July 1997.
|
Oesterling, Joseph E. |
|
1998 |
1-20 |
4S1 |
p. 58-63 6 p. |
artikel |
15 |
Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia
|
Alberts, Steven R. |
|
2001 |
1-20 |
4S1 |
p. 188-190 3 p. |
artikel |
16 |
Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein
|
Bosland, Maarten C |
|
2001 |
1-20 |
4S1 |
p. 202-204 3 p. |
artikel |
17 |
Childbirth-induced trauma to the urethral continence mechanism: review and recommendations
|
Baessler, Kaven |
|
2003 |
1-20 |
4S1 |
p. 39-44 6 p. |
artikel |
18 |
Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women
|
Moyad, Mark A |
|
2002 |
1-20 |
4S1 |
p. 20-33 14 p. |
artikel |
19 |
Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research
|
Moyad, Mark A |
|
2002 |
1-20 |
4S1 |
p. 34-40 7 p. |
artikel |
20 |
Comprehensive Patient Evaluation for Benign Prostatic Hyperplasia
|
Jepsen, Jan V |
|
1998 |
1-20 |
4S1 |
p. 13-18 6 p. |
artikel |
21 |
Computer-assisted image analysis–derived intermediate endpoints
|
Boone, Charles W. |
|
2001 |
1-20 |
4S1 |
p. 129-131 3 p. |
artikel |
22 |
Current Trends in Management of Men With Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
|
Holtgrewe, H.Logan |
|
1998 |
1-20 |
4S1 |
p. 1-7 7 p. |
artikel |
23 |
Design considerations for efficient prostate cancer chemoprevention trials
|
Lee, J.Jack |
|
2001 |
1-20 |
4S1 |
p. 205-212 8 p. |
artikel |
24 |
Dietary fat reduction to reduce prostate cancer risk: controlled enthusiasm, learning a lesson from breast or other cancers, and the big picture
|
Moyad, Mark A |
|
2002 |
1-20 |
4S1 |
p. 51-62 12 p. |
artikel |
25 |
Dietary trial in prostate cancer: Early experience and implications for clinical trial design
|
Ornish, Dean M |
|
2001 |
1-20 |
4S1 |
p. 200-201 2 p. |
artikel |
26 |
Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints 1 1 The views expressed in this article do not necessarily represent those of or imply endorsement from the US Food and Drug Administration or the US government. Pursuant to 5 CFR §2635.807(b)(2), federal employees are required to include the preceding statement.
|
Keegan, Patricia |
|
2001 |
1-20 |
4S1 |
p. 216-219 4 p. |
artikel |
27 |
Epidemiology and natural history of urinary incontinence in women
|
Hunskaar, Steinar |
|
2003 |
1-20 |
4S1 |
p. 16-23 8 p. |
artikel |
28 |
Evaluation and follow-up of patients with n1-3 m0 or nxm1 prostate cancer in phase iii trials
|
Hall, Reginald |
|
1997 |
1-20 |
4S1 |
p. 39-45 7 p. |
artikel |
29 |
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations
|
Lieberman, Ronald |
|
2001 |
1-20 |
4S1 |
p. 4-27 24 p. |
artikel |
30 |
Foreword
|
Tindall, Donald J. |
|
2001 |
1-20 |
4S1 |
p. vii- 1 p. |
artikel |
31 |
Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia
|
Sakr, Wael A |
|
2001 |
1-20 |
4S1 |
p. 115-120 6 p. |
artikel |
32 |
Home electrical stimulation for urinary incontinence: a study of the diffusion ofa new technology
|
Indrekvam, Solfrid |
|
2003 |
1-20 |
4S1 |
p. 24-30 7 p. |
artikel |
33 |
How is quality of life in prostate cancer patients influenced by modern treatment? the wallenberg symposium
|
Altwein, Jens |
|
1997 |
1-20 |
4S1 |
p. 66-76 11 p. |
artikel |
34 |
Imaging and prostate cancer chemoprevention:
|
Littrup, Peter J |
|
2001 |
1-20 |
4S1 |
p. 121-123 3 p. |
artikel |
35 |
Introduction
|
Moyad, Mark A. |
|
2002 |
1-20 |
4S1 |
p. 1-3 3 p. |
artikel |
36 |
Introduction
|
Cardozo, Linda D. |
|
2003 |
1-20 |
4S1 |
p. 1-2 2 p. |
artikel |
37 |
Introduction
|
Lieberman, Ronald |
|
2001 |
1-20 |
4S1 |
p. 1-3 3 p. |
artikel |
38 |
Introduction
|
Andersson, Lennart |
|
1997 |
1-20 |
4S1 |
p. 1-2 2 p. |
artikel |
39 |
Introduction
|
Marks, Leonard S. |
|
|
1-20 |
4S1 |
p. 1 |
artikel |
40 |
Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective
|
Moyad, Mark A |
|
2002 |
1-20 |
4S1 |
p. 41-50 10 p. |
artikel |
41 |
Long-Term Implications of Medical Therapy on Benign Prostatic Hyperplasia End Points
|
Nickel, J.Curtis |
|
1998 |
1-20 |
4S1 |
p. 50-57 8 p. |
artikel |
42 |
Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials
|
Kurhanewicz, John |
|
2001 |
1-20 |
4S1 |
p. 124-128 5 p. |
artikel |
43 |
Meta-Analysis of Randomized Clinical Trials of Finasteride
|
Roehrborn, Claus G |
|
1998 |
1-20 |
4S1 |
p. 46-49 4 p. |
artikel |
44 |
Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk—an unmeasured and masked mediator of potential significance?
|
Moyad, Mark A. |
|
2002 |
1-20 |
4S1 |
p. 4-8 5 p. |
artikel |
45 |
Minimally Invasive Alternative Therapeutic Options for Lower Urinary Tract Symptoms
|
Kaplan MD, Steven A |
|
1998 |
1-20 |
4S1 |
p. 32-37 6 p. |
artikel |
46 |
Natural History and Epidemiology of Benign Prostatic Hyperplasia: Relationship Among Urologic Measures
|
Girman, Cynthia J |
|
1998 |
1-20 |
4S1 |
p. 8-12 5 p. |
artikel |
47 |
New biologicals for prostate cancer prevention:
|
Pantuck, Allan J |
|
2001 |
1-20 |
4S1 |
p. 95-99 5 p. |
artikel |
48 |
New concepts in the pathology of prostatic epithelial carcinogenesis
|
De Marzo, Angelo M |
|
2001 |
1-20 |
4S1 |
p. 103-114 12 p. |
artikel |
49 |
New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents
|
Williams, Elizabeth D |
|
2001 |
1-20 |
4S1 |
p. 100-102 3 p. |
artikel |
50 |
New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics
|
Paweletz, Cloud P |
|
2001 |
1-20 |
4S1 |
p. 160-163 4 p. |
artikel |
51 |
Other novel agents: Rationale and current status as chemopreventive agents
|
Tolcher, Anthony W |
|
2001 |
1-20 |
4S1 |
p. 86-89 4 p. |
artikel |
52 |
Overview of α-Blocker Therapy for Benign Prostatic Hyperplasia
|
Narayan, Perinchery |
|
1998 |
1-20 |
4S1 |
p. 38-45 8 p. |
artikel |
53 |
Oxidative stress in chemoprevention trials
|
DeWeese, Theodore L. |
|
2001 |
1-20 |
4S1 |
p. 137-140 4 p. |
artikel |
54 |
Percutaneous computed tomography–guided radiofrequency ablation of renal masses in high surgical risk patients: preliminary results
|
Su, L.i-Ming |
|
|
1-20 |
4S1 |
p. 26-33 |
artikel |
55 |
Pharmacologic treatment of stress urinary incontinence: expectations for outcome
|
Schuessler, Bernhard |
|
2003 |
1-20 |
4S1 |
p. 31-38 8 p. |
artikel |
56 |
Phase II studies on prostate cancer
|
Schröder, Fritz H. |
|
1997 |
1-20 |
4S1 |
p. 3-14 12 p. |
artikel |
57 |
Planning controlled clinical trials
|
Denis, Louis |
|
1997 |
1-20 |
4S1 |
p. 15-26 12 p. |
artikel |
58 |
Potential target populations and clinical models for testing chemopreventive agents
|
Klein, Eric A |
|
2001 |
1-20 |
4S1 |
p. 171-173 3 p. |
artikel |
59 |
Preprostatectomy: A clinical model to study stromal-epithelial interactions
|
Lopaczynski, Wlodek |
|
2001 |
1-20 |
4S1 |
p. 194-199 6 p. |
artikel |
60 |
Proapoptotic anti-inflammatory drugs
|
Myers, Charles |
|
2001 |
1-20 |
4S1 |
p. 73-76 4 p. |
artikel |
61 |
Prostate cancer chemoprevention: Strategies for designing efficient clinical trials
|
Lieberman, Ronald |
|
2001 |
1-20 |
4S1 |
p. 224-229 6 p. |
artikel |
62 |
Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents
|
Nelson, William G |
|
2001 |
1-20 |
4S1 |
p. 56-63 8 p. |
artikel |
63 |
Prostate cancer prevention strategies using antiproliferative or differentiating agents
|
Walczak, Janet |
|
2001 |
1-20 |
4S1 |
p. 81-85 5 p. |
artikel |
64 |
Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents
|
Partin, Alan W |
|
2001 |
1-20 |
4S1 |
p. 132-136 5 p. |
artikel |
65 |
Prostate-specific antigen–enhanced testing and risk stratification for chemoprevention trials 1 1 The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Army or the Department of Defense.
|
Moul, Judd W |
|
2001 |
1-20 |
4S1 |
p. 174-177 4 p. |
artikel |
66 |
Quality of Life endpoints in prostate chemoprevention trials
|
Sloan, Jeff A |
|
2001 |
1-20 |
4S1 |
p. 235-240 6 p. |
artikel |
67 |
Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia
|
Clark, Larry C |
|
2001 |
1-20 |
4S1 |
p. 185-187 3 p. |
artikel |
68 |
Recent Developments in the Surgical Management of Benign Prostatic Hyperplasia
|
Jepsen, Jan V |
|
1998 |
1-20 |
4S1 |
p. 23-31 9 p. |
artikel |
69 |
Robotic radical prostatectomy and the vattikuti urology institute technique: an interim analysis of results and technical points
|
Menon, Mani |
|
|
1-20 |
4S1 |
p. 15-20 |
artikel |
70 |
Selective estrogen receptor modulators for the chemoprevention of prostate cancer
|
Steiner, Mitchell S |
|
2001 |
1-20 |
4S1 |
p. 68-72 5 p. |
artikel |
71 |
Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?
|
Moyad, Mark A |
|
2002 |
1-20 |
4S1 |
p. 9-19 11 p. |
artikel |
72 |
Sequence databases and microarrays as tools for identifying prostate cancer biomarkers
|
Grouse, Lynette H |
|
2001 |
1-20 |
4S1 |
p. 154-159 6 p. |
artikel |
73 |
Serotonergic modulation of bladder afferent pathways
|
Burgard, Edward C |
|
2003 |
1-20 |
4S1 |
p. 10-15 6 p. |
artikel |
74 |
Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence
|
Thor, Karl B |
|
2003 |
1-20 |
4S1 |
p. 3-9 7 p. |
artikel |
75 |
Similarities of prostate and breast cancer: Evolution, diet, and estrogens
|
Coffey, Donald S |
|
2001 |
1-20 |
4S1 |
p. 31-38 8 p. |
artikel |
76 |
Standardization, analytical validation, and quality control of intermediate endpoint biomarkers
|
Veltri, Robert W |
|
2001 |
1-20 |
4S1 |
p. 164-170 7 p. |
artikel |
77 |
State of research for prostate cancer: Excerpt∗ from the report of the Prostate Cancer Progress Review Group∗ ∗ For the full report, see: http://osp.nci.nih.gov/prgreports/pprgreport/toc.htm
|
Tindall, Donald J. |
|
2001 |
1-20 |
4S1 |
p. 28-30 3 p. |
artikel |
78 |
Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial
|
Hellstrom, Wayne J.G. |
|
|
1-20 |
4S1 |
p. 8-14 |
artikel |
79 |
Sustaining the effort for cancer prevention
|
Aldigé, Carolyn |
|
2001 |
1-20 |
4S1 |
p. 52-55 4 p. |
artikel |
80 |
Telomerase activity modulation in the prevention of prostate cancer
|
Kim, Nam W. |
|
2001 |
1-20 |
4S1 |
p. 148-153 6 p. |
artikel |
81 |
The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention
|
Nelson, William G |
|
2001 |
1-20 |
4S1 |
p. 39-45 7 p. |
artikel |
82 |
The Prostate Cancer Prevention Trial: Current status and lessons learned
|
Thompson Jr, Ian M |
|
2001 |
1-20 |
4S1 |
p. 230-234 5 p. |
artikel |
83 |
The role of dihydrotestosterone in benign prostatic hyperplasia
|
Carson III, Culley |
|
|
1-20 |
4S1 |
p. 2-7 |
artikel |
84 |
The role of estrogens in female lower urinary tract dysfunction
|
Robinson, Dudley |
|
2003 |
1-20 |
4S1 |
p. 45-51 7 p. |
artikel |
85 |
The role of prostate needle biopsy in evaluation of chemopreventive agents
|
Marks, Leonard S |
|
2001 |
1-20 |
4S1 |
p. 191-193 3 p. |
artikel |
86 |
Trends toward less invasive treatment of female stress urinary incontinence
|
Balmforth, James |
|
2003 |
1-20 |
4S1 |
p. 52-60 9 p. |
artikel |
87 |
Trial endpoints for drug approval in oncology: Chemoprevention 1 1 This article is not an official FDA guidance or policy statement. No official support or endorsement by the Food and Drug Administration is intended or should be inferred.
|
Beitz, Julie |
|
2001 |
1-20 |
4S1 |
p. 213-215 3 p. |
artikel |
88 |
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer
|
Bergan, Raymond C |
|
2001 |
1-20 |
4S1 |
p. 77-80 4 p. |
artikel |
89 |
Urethrolysis with martius labial fat pad graft for iatrogenic bladder outlet obstruction
|
Carey, Jeffrey M. |
|
|
1-20 |
4S1 |
p. 21-25 |
artikel |
90 |
Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials
|
Trock, Bruce J |
|
2001 |
1-20 |
4S1 |
p. 241-247 7 p. |
artikel |